Related Experiment Videos
[Specific immunotherapy of prostate carcinoma]
Urologia Internationalis
|January 1, 1983
Summary
Chessboard vaccination, a novel immunotherapy, shows promise for prostate cancer treatment. This approach, combined with hormone therapy, significantly improved survival rates and remission in patients with advanced prostate carcinomas.
Area of Science:
- Oncology
- Immunology
- Urology
Context:
- Female sex hormone treatment has been the standard for prostate carcinoma.
- A new therapeutic approach, specific immunotherapy, is explored.
- Chessboard vaccination is a novel method involving intracutaneous injection of inactivated cancer cells with neuraminidase.
Purpose:
- To evaluate the efficacy of chessboard vaccination as a specific immunotherapy for prostate carcinoma.
- To assess its effectiveness in conjunction with hormone therapy.
- To determine its potential as an alternative treatment, especially for hormone-independent or estrogen-intolerant cases.
Summary:
- Chessboard vaccination, alongside hormone therapy, demonstrated a long-term therapeutic effect in approximately 50% of patients.
- Effectiveness was evidenced by decreased serum phosphatases and carcinoembryonic antigen.
- Scintigraphic evidence showed remission of osteometastases, and a statistically significant increase in survival rate was observed in metastatic prostate carcinomas.
Impact:
- Specific immunotherapy via chessboard vaccination offers a new therapeutic alternative for prostate cancer.
- It is particularly beneficial for hormone-independent prostate carcinomas.
- It provides a viable option for patients with estrogen intolerance or when hormone therapy is ineffective.